Outsourcing made easy with a one-stop solution to early phase drug development.
We are an integrated drug development solution company, offering pharmaceutical and biotechnology companies a proven, flexible approach that removes the need for multiple service providers during the early stages of drug development. Whether for one study or an end-to-end program, we help you reach critical decision-making milestones sooner by improving speed and ease from lead candidate selection to clinical proof of concept, and beyond. When partnering with Altasciences, you can experience up to 40% in time savings thanks to our integrated, one-stop solution offering.
We strive to create a true partnership with our clients, our partners, and our colleagues that enables a mutually supporting relationship built on a combination of excellent science and solid communication.
Helping sponsors get better drugs to the people who need them, faster, for over 25 years.
Our full-service offering is always tailored to your specific research needs:
- Preclinical research
- Clinical pharmacology
- Drug formulation
- Manufacturing and analytical services
- Bioanalysis
- Program management
- Medical writing
- Biostatics
- Data management
- And so much more!
We are an integrated drug development solution company, offering pharmaceutical and biotechnology companies a proven, flexible approach that removes the need for multiple service providers during the early stages of drug development. Whether for one study or an end-to-end program, we help you reach critical decision-making milestones sooner by improving speed and ease from lead candidate selection to clinical proof of concept, and beyond. When partnering with Altasciences, you can experience up to 40% in time savings thanks to our integrated, one-stop solution offering.
We strive to create a true partnership with our clients, our partners, and our colleagues that enables a mutually supporting relationship built on a combination of excellent science and solid communication.
Helping sponsors get better drugs to the people who need them, faster, for over 25 years.
Our full-service offering is always tailored to your specific research needs:
- Preclinical research
- Clinical pharmacology
- Drug formulation
- Manufacturing and analytical services
- Bioanalysis
- Program management
- Medical writing
- Biostatics
- Data management
- And so much more!
Location: United States, Pennsylvania, Scott
Employees: 1001-5000
Founded date: 1992
Investors 2
| Date | Name | Website |
| - | Audax Priv... | audaxpriva... |
| - | Signet Hea... | signetheal... |
Mentions in press and media 26
| Date | Title | Description |
| 21.03.2023 | Altasciences Selects Proscia To Accelerate The Development Of Life-Saving Drugs | “Our decision to adopt digital pathology and chart our course with Proscia strongly reflects Altasciences’ guiding focus on ensuring our sponsors’ success,” said Dr. Wendell P. Davis, Vice President of Pathology. LAVAL, Québec and PHILADELP... |
| 17.01.2022 | Altasciences Acquires Sinclair Research and Continues to Expand Preclinical Platform | LAVAL, Quebec--(BUSINESS WIRE)--Altasciences, an integrated CRO/CDMO offering pharmaceutical and biotechnology companies a seamless solution to early-stage drug development from lead candidate selection to clinical proof of concept, announc... |
| 07.01.2022 | Fujifilm Diosynth adds on at its NC hub, bolstering lab space with plans to bring on 145 new jobs | New year, same Fujifilm Diosynth. The CDMO giant hit the ground running at full speed this year, announcing it will expand its BioProcess Innovation Center in Research Triangle Park, NC. The move will double its existing ... |
| 06.01.2022 | Novo Holdings picks up injectables CDMO in push for single-use manufacturing tech | Roger Perlmutter hasn’t wasted any time since announcing his supposed retirement from Merck in October 2020. After leaving his perch as one of the most successful R&D chiefs in Big Pharma, he’s now snatching a cool half-billion dollars ... |
| 06.01.2022 | A year after expansion in Pennsylvania, Altasciences scoops up CRO to spread to Midwest | Altasciences CEO Chris Perkin has gone through several acquisitions in his 45-year career. And if there’s one thing he learned, it’s how not to go through an acquisition. His company put that knowledge to use on Tuesday when ... |
| 06.01.2022 | Covid-19 manufacturing roundup: Ritonavir production to reach 100M doses annually; Schumer calls for a boost to domestic vaccine supply | Amid the spike in positive Covid-19 cases thanks to the Omicron variant, Ascletis will expand its production of the oral tablet ritonavir to produce 100 million doses a year. And the company is ready to increase that numb... |
| 06.01.2022 | Pfizer and other biopharmas to FDA: Don't include CMOs in new reporting requirements on drug volume | As the FDA is looking to reduce drug shortages further by collecting more data on the volume of drugs and APIs manufactured worldwide, companies like Pfizer, Thermo Fisher, Viatris and industry groups are pushing back ... |
| 06.01.2022 | Sosei and Verily partner on GPCRs; ObsEva touts PhIII data in endometriosis pain | Sosei Heptares is teaming up with a big-name partner: Alphabet’s Verily. No financials were disclosed, but the pair will aim to use Verily’s immune profiling and Sosei Heptares’ GPCR drug design capabilities to devel... |
| 06.01.2022 | Pfizer and other biopharmas to FDA: Don't include CMOs in new reporting requirements on drug volume | Throughout the past two years, North Carolina Gov. Roy Cooper has been building a biotech manufacturing empire in his state, expanding beyond the Research Triangle and offering tax breaks to international companies. Now, a new project is in... |
| 06.01.2022 | Pfizer and other biopharmas to FDA: Don't include CMOs in new reporting requirements on drug volume | Eli Lilly is beefing up its fleet of vehicles being deployed to carry drugs to the brain. Enlisting Canada’s Entos Pharmaceuticals, Eli Lilly has grabbed rights to a suite of proteo-lipid vehicles (PLVs) as part of a research collaboration ... |
Show more